Repositioning Candidates

Repositioning candidates for NAFLD are derived from DrugBank which fall into three categories: therapeutic strategy-associated, target-associated, and indication-associated candidates. For each candidate, detailed properties are extracted from DrugBank, and related strategies, target and NAFLD-associated disease in NAFLDkb are presented with knowledge graphs.

stats1
stats2
stats3
1608 records.
Candidate ID Source ID Source Type Compound Type Candidate Name Inclusion Criteria
R0101 DB00278 approved; investigational small molecule Argatroban Therapeutic strategy associated Details
R0102 DB00279 approved; vet_approved small molecule Liothyronine Target associated Details
R0103 DB00281 approved; vet_approved small molecule Lidocaine Therapeutic strategy associated Details
R0104 DB00282 approved small molecule Pamidronic acid Therapeutic strategy associated Details
R0105 DB00286 approved small molecule Conjugated estrogens Indication associated Details
R0106 DB00287 approved small molecule Travoprost Indication associated Details
R0107 DB00288 approved small molecule Amcinonide Therapeutic strategy associated Details
R0108 DB00301 approved; investigational small molecule Flucloxacillin Indication associated Details
R0109 DB00303 approved; investigational small molecule Ertapenem Indication associated Details
R0110 DB00308 approved small molecule Ibutilide Indication associated Details
R0111 DB00310 approved small molecule Chlorthalidone Therapeutic strategy associated Details
R0112 DB00313 approved; investigational small molecule Valproic acid Therapeutic strategy associated Details
R0113 DB00321 approved small molecule Amitriptyline Indication associated Details
R0114 DB00324 approved; investigational small molecule Fluorometholone Therapeutic strategy associated Details
R0115 DB00325 approved; investigational small molecule Nitroprusside Indication associated Details
R0116 DB00326 approved small molecule Calcium glucoheptonate Indication associated Details
R0117 DB00328 approved; investigational small molecule Indomethacin Therapeutic strategy associated Details
R0118 DB00333 approved small molecule Methadone Therapeutic strategy associated Details
R0119 DB00334 approved; investigational small molecule Olanzapine Indication associated Details
R0120 DB00335 approved small molecule Atenolol Therapeutic strategy associated Details
R0121 DB00337 approved; investigational small molecule Pimecrolimus Therapeutic strategy associated Details
R0122 DB00341 approved small molecule Cetirizine Therapeutic strategy associated Details
R0123 DB00343 approved; investigational small molecule Diltiazem Therapeutic strategy associated Details
R0124 DB00344 approved small molecule Protriptyline Indication associated Details
R0125 DB00346 approved; investigational small molecule Alfuzosin Therapeutic strategy associated Details
R0126 DB00350 approved; investigational small molecule Minoxidil Therapeutic strategy associated Details
R0127 DB00351 approved; investigational; vet_approved small molecule Megestrol acetate Therapeutic strategy associated Details
R0128 DB00356 approved small molecule Chlorzoxazone Therapeutic strategy associated Details
R0129 DB00360 approved; investigational small molecule Sapropterin Therapeutic strategy associated Details
R0130 DB00361 approved; investigational small molecule Vinorelbine Therapeutic strategy associated Details
R0131 DB00365 approved; investigational; withdrawn small molecule Grepafloxacin Indication associated Details
R0132 DB00367 approved; investigational small molecule Levonorgestrel Indication associated Details
R0133 DB00373 approved small molecule Timolol Indication associated Details
R0134 DB00374 approved; investigational small molecule Treprostinil Therapeutic strategy associated Details
R0135 DB00375 approved small molecule Colestipol Indication associated Details
R0136 DB00380 approved; withdrawn small molecule Dexrazoxane Therapeutic strategy associated Details
R0137 DB00381 approved small molecule Amlodipine Therapeutic strategy associated Details
R0138 DB00384 approved small molecule Triamterene Therapeutic strategy associated Details
R0139 DB00394 approved; investigational small molecule Beclomethasone dipropionate Therapeutic strategy associated Details
R0140 DB00397 approved; vet_approved; withdrawn small molecule Phenylpropanolamine Indication associated Details
R0141 DB00399 approved small molecule Zoledronic acid Therapeutic strategy associated Details
R0142 DB00401 approved small molecule Nisoldipine Indication associated Details
R0143 DB00404 approved; illicit; investigational small molecule Alprazolam Indication associated Details
R0144 DB00414 approved; investigational; withdrawn small molecule Acetohexamide Indication associated Details
R0145 DB00436 approved small molecule Bendroflumethiazide Therapeutic strategy associated Details
R0146 DB00438 approved small molecule Ceftazidime Indication associated Details
R0147 DB00439 approved; withdrawn small molecule Cerivastatin Target associated Details
R0148 DB00440 approved; vet_approved small molecule Trimethoprim Indication associated Details
R0149 DB00441 approved small molecule Gemcitabine Therapeutic strategy associated Details
R0150 DB00443 approved; vet_approved small molecule Betamethasone Therapeutic strategy associated Details
R0151 DB00447 approved; investigational; withdrawn small molecule Loracarbef Indication associated Details
R0152 DB00457 approved small molecule Prazosin Indication associated Details
R0153 DB00458 approved small molecule Imipramine Indication associated Details
R0154 DB00460 approved; investigational small molecule Verteporfin Therapeutic strategy associated Details
R0155 DB00461 approved small molecule Nabumetone Therapeutic strategy associated Details
R0156 DB00464 approved; investigational small molecule Sodium tetradecyl sulfate Therapeutic strategy associated Details
R0157 DB00465 approved small molecule Ketorolac Therapeutic strategy associated Details
R0158 DB00467 approved; investigational small molecule Enoxacin Indication associated Details
R0159 DB00469 approved small molecule Tenoxicam Therapeutic strategy associated Details
R0160 DB00472 approved; vet_approved small molecule Fluoxetine Indication associated Details
R0161 DB00476 approved small molecule Duloxetine Therapeutic strategy associated Details
R0162 DB00479 approved; investigational; vet_approved small molecule Amikacin Indication associated Details
R0163 DB00480 approved small molecule Lenalidomide Therapeutic strategy associated Details
R0164 DB00481 approved; investigational small molecule Raloxifene Therapeutic strategy associated Details
R0165 DB00482 approved; investigational small molecule Celecoxib Therapeutic strategy associated Details
R0166 DB00484 approved small molecule Brimonidine Therapeutic strategy associated Details
R0167 DB00487 approved small molecule Pefloxacin Indication associated Details
R0168 DB00489 approved small molecule Sotalol Indication associated Details
R0169 DB00491 approved small molecule Miglitol Indication associated Details
R0170 DB00492 approved small molecule Fosinopril Indication associated Details
R0171 DB00498 approved; investigational small molecule Phenindione Indication associated Details
R0172 DB00500 approved small molecule Tolmetin Therapeutic strategy associated Details
R0173 DB00504 approved small molecule Levallorphan Indication associated Details
R0174 DB00509 approved; investigational small molecule Dextrothyroxine Target associated Details
R0175 DB00519 approved small molecule Trandolapril Indication associated Details
R0176 DB00521 approved small molecule Carteolol Indication associated Details
R0177 DB00524 approved small molecule Metolazone Therapeutic strategy associated Details
R0178 DB00528 approved; investigational small molecule Lercanidipine Indication associated Details
R0179 DB00533 approved; investigational; withdrawn small molecule Rofecoxib Therapeutic strategy associated Details
R0180 DB00535 approved small molecule Cefdinir Indication associated Details
R0181 DB00537 approved; investigational small molecule Ciprofloxacin Indication associated Details
R0182 DB00539 approved; investigational small molecule Toremifene Therapeutic strategy associated Details
R0183 DB00540 approved small molecule Nortriptyline Indication associated Details
R0184 DB00542 approved; investigational small molecule Benazepril Indication associated Details
R0185 DB00543 approved small molecule Amoxapine Indication associated Details
R0186 DB00547 approved small molecule Desoximetasone Therapeutic strategy associated Details
R0187 DB00549 approved; investigational small molecule Zafirlukast Therapeutic strategy associated Details
R0188 DB00554 approved; investigational small molecule Piroxicam Therapeutic strategy associated Details
R0189 DB00555 approved; investigational small molecule Lamotrigine Indication associated Details
R0190 DB00557 approved small molecule Hydroxyzine Therapeutic strategy associated Details
R0191 DB00559 approved; investigational small molecule Bosentan Indication associated Details
R0192 DB00560 approved small molecule Tigecycline Indication associated Details
R0193 DB00562 approved small molecule Benzthiazide Therapeutic strategy associated Details
R0194 DB00563 approved small molecule Methotrexate Therapeutic strategy associated Details
R0195 DB00569 approved; investigational small molecule Fondaparinux Indication associated Details
R0196 DB00571 approved; investigational small molecule Propranolol Therapeutic strategy associated Details
R0197 DB00573 approved small molecule Fenoprofen Target associated Details
R0198 DB00574 approved; illicit; investigational; withdrawn small molecule Fenfluramine Therapeutic strategy associated Details
R0199 DB00575 approved small molecule Clonidine Indication associated Details
R0200 DB00580 approved; investigational; withdrawn small molecule Valdecoxib Therapeutic strategy associated Details